Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

NCT01399593 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

102

Enrollment

INDUSTRY

Sponsor class

Stopped Did not achieve statistical significance for primary endpoint

Conditions

Antibody Mediated Rejection

Interventions

DRUG: Eculizumab

Sponsor

Alexion Pharmaceuticals, Inc.